Birgitte Volck

Nature Reviews Drug Discovery 16, 378 (2017). doi:10.1038/nrd.2017.105 Small patient populations are big business. In 2000, worldwide sales of orphan drugs for rare diseases accounted for just 6% of global prescription drug sales. Last year they accounted for US$114 billion in revenue and nearly 16% of total prescription drug sales, and they are on track to account for 21% of sales by 2022. For Birgitte Volck, head of rare disease R&D at GlaxoSmithKline, the explosion of this space has tracked with the arrival of a new era in rare disease drug discovery and development. She told Asher Mullard about how new drug modalities, the voice of the patient and genomics are reshaping the field.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research